IgA2 Inhibitors

The realm of IgA2 inhibitors predominantly revolves around compounds that can influence the broader immune system and the production of antibodies, rather than targeting IgA2 directly. Most of these compounds impact B-cell activity, the primary cells responsible for antibody production. For instance, Cyclosporine A and Corticosteroids both function as immunosuppressants, with the ability to attenuate the production of antibodies, including IgA2. Similarly, agents like Chlorambucil, an alkylating agent, suppress B-cell activity, which subsequently can curtail IgA2 production.

FTY720, also known as Fingolimod, takes a unique approach by modulating immune cell trafficking. By reducing B-cell activity in circulation, it indirectly influences IgA2 production. On the other hand, Mycophenolic acid interferes with purine synthesis, impacting B-cell function and leading to a potential decrease in IgA2 levels. Methotrexate, Azathioprine, and Leflunomide all have mechanisms tied to B-cell suppression, either through antimetabolite activity or through other metabolic interference, which can result in attenuated IgA2 levels.